原发性胆汁性胆管炎的流行病学、发病机制及治疗进展
Epidemiology, Pathogenesis and Treatment Progress of Primary Biliary Cholangitis
摘要: 原发性胆汁性胆管炎是一种慢性自身免疫性胆汁淤积性疾病，主要发生在中老年女性，PBC的发病率和患病率在不同地区和时期差异性较大。原发性胆汁性胆管炎的发病机制尚不明确，现普遍认为PBC的发病涉及遗传因素、环境因素和免疫因素。目前，除了熊去氧胆酸(UDCA)、奥贝胆酸以及贝特类药物被批准用于PBC患者的治疗，更多的新型药物以及治疗方法正处于临床研发的不同阶段。
Abstract: Primary biliary cholangitis is a chronic autoimmune cholestasis disease, mainly occurring in middle-aged and elderly women. The incidence and prevalence of PBC vary greatly in different regions and periods. The pathogenesis of primary biliary cholangitis is still unclear, but it is generally believed that the pathogenesis of PBC involves genetic factors, environmental factors and immune factors. At present, in addition to Ursodeoxycholic Acid (UDCA), obecholic acid and bate drugs are approved for the treatment of PBC patients, more new drugs and treatments are in different stages of clinical research and development.
文章引用：余兴丹, 曾爱中. 原发性胆汁性胆管炎的流行病学、发病机制及治疗进展[J]. 临床医学进展, 2025, 15(3): 153-160. https://doi.org/10.12677/acm.2025.153599

参考文献

[1] Selmi, C., Bowlus, C.L., Gershwin, M.E. and Coppel, R.L. (2011) Primary Biliary Cirrhosis. The Lancet, 377, 1600-1609. [Google Scholar] [CrossRef] [PubMed]
[2] Bhandari, B.M., Bayat, H. and Rothstein, K.D. (2011) Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 40, 373-386. [Google Scholar] [CrossRef] [PubMed]
[3] Lee, H.E., Churg, A., Ryu, J.H., Bilawich, A.M., Larsen, B.T., Tazelaar, H.D., et al. (2018) Histopathologic Findings in Lung Biopsies from Patients with Primary Biliary Cholangitis. Human Pathology, 82, 177-186. [Google Scholar] [CrossRef] [PubMed]
[4] Trivella, J., John, B.V. and Levy, C. (2023) Primary Biliary Cholangitis: Epidemiology, Prognosis, and Treatment. Hepatology Communications, 7, e0179. [Google Scholar] [CrossRef] [PubMed]
[5] Lv, L., Fang, D., Shi, D., Chen, D., Yan, R., Zhu, Y., et al. (2016) Alterations and Correlations of the Gut Microbiome, Metabolism and Immunity in Patients with Primary Biliary Cirrhosis. Environmental Microbiology, 18, 2272-2286. [Google Scholar] [CrossRef] [PubMed]
[6] Xin, L. and Xin, Y. (2023) Genetic Predisposition of the Gastrointestinal Microbiome and Primary Biliary Cholangitis: A Bi-Directional, Two-Sample Mendelian Randomization Analysis. Frontiers in Endocrinology, 14, Article 1225742. [Google Scholar] [CrossRef] [PubMed]
[7] Houri, I. and Hirschfield, G.M. (2024) Primary Biliary Cholangitis. Clinics in Liver Disease, 28, 79-92. [Google Scholar] [CrossRef] [PubMed]
[8] Metcalf, J., Bhopal, R., Gray, J., Howel, D. and James, O. (1997) Incidence and Prevalence of Primary Biliary Cirrhosis in the City of Newcastle Upon Tyne, England. International Journal of Epidemiology, 26, 830-836. [Google Scholar] [CrossRef] [PubMed]
[9] Colapietro, F., Bertazzoni, A. and Lleo, A. (2022) Contemporary Epidemiology of Primary Biliary Cholangitis. Clinics in Liver Disease, 26, 555-570. [Google Scholar] [CrossRef] [PubMed]
[10] Lleo, A., Wang, G., Gershwin, M.E. and Hirschfield, G.M. (2020) Primary Biliary Cholangitis. The Lancet, 396, 1915-1926. [Google Scholar] [CrossRef] [PubMed]
[11] Lv, T., Chen, S., Li, M., Zhang, D., Kong, Y. and Jia, J. (2020) Regional Variation and Temporal Trend of Primary Biliary Cholangitis Epidemiology: A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology, 36, 1423-1434. [Google Scholar] [CrossRef] [PubMed]
[12] Murillo Perez, C.F., Goet, J.C., Lammers, W.J., Gulamhusein, A., van Buuren, H.R., Ponsioen, C.Y., et al. (2018) Milder Disease Stage in Patients with Primary Biliary Cholangitis over a 44‐Year Period: A Changing Natural History. Hepatology, 67, 1920-1930. [Google Scholar] [CrossRef] [PubMed]
[13] Gulamhusein, A.F. and Hirschfield, G.M. (2019) Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities. Nature Reviews Gastroenterology & Hepatology, 17, 93-110. [Google Scholar] [CrossRef] [PubMed]
[14] Gerussi, A., Asselta, R. and Invernizzi, P. (2022) Genetics of Primary Biliary Cholangitis. Clinics in Liver Disease, 26, 571-582. [Google Scholar] [CrossRef] [PubMed]
[15] Hirschfield, G. and Invernizzi, P. (2011) Progress in the Genetics of Primary Biliary Cirrhosis. Seminars in Liver Disease, 31, 147-156. [Google Scholar] [CrossRef] [PubMed]
[16] Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., et al. (2012) Genome-Wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. The American Journal of Human Genetics, 91, 721-728. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, J.Z., Almarri, M.A., Gaffney, D.J., Mells, G.F., Jostins, L., Cordell, H.J., et al. (2012) Dense Fine-Mapping Study Identifies New Susceptibility Loci for Primary Biliary Cirrhosis. Nature Genetics, 44, 1137-1141. [Google Scholar] [CrossRef] [PubMed]
[18] Tsuchiya, N. and Ohashi, J. (2015) Human Immune System Diversity and Its Implications in Diseases. Journal of Human Genetics, 60, 655-656. [Google Scholar] [CrossRef] [PubMed]
[19] Cordell, H.J., Fryett, J.J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., et al. (2021) An International Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs. Journal of Hepatology, 75, 572-581. [Google Scholar] [CrossRef] [PubMed]
[20] Asselta, R., Paraboschi, E.M., Gerussi, A., Cordell, H.J., Mells, G.F., Sandford, R.N., et al. (2021) X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 160, 2483-2495.E26. [Google Scholar] [CrossRef] [PubMed]
[21] Tanaka, A., Ma, X., Takahashi, A. and Vierling, J.M. (2024) Primary Biliary Cholangitis. The Lancet, 404, 1053-1066. [Google Scholar] [CrossRef] [PubMed]
[22] Wijarnpreecha, K., Werlang, M., Panjawatanan, P., Kroner, P.T., Mousa, O.Y., Pungpapong, S., et al. (2019) Association between Smoking and Risk of Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases, 28, 197-203. [Google Scholar] [CrossRef] [PubMed]
[23] Prince, M.I., Ducker, S.J. and James, O.F.W. (2010) Case-Control Studies of Risk Factors for Primary Biliary Cirrhosis in Two United Kingdom Populations. Gut, 59, 508-512. [Google Scholar] [CrossRef] [PubMed]
[24] Corpechot, C., Chrétien, Y., Chazouillères, O. and Poupon, R. (2010) Demographic, Lifestyle, Medical and Familial Factors Associated with Primary Biliary Cirrhosis. Journal of Hepatology, 53, 162-169. [Google Scholar] [CrossRef] [PubMed]
[25] Gershwin, E.M., Selmi, C., Worman, H.J., Gold, E.B., Watnik, M., Utts, J., et al. (2005) Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients. Hepatology, 42, 1194-1202. [Google Scholar] [CrossRef] [PubMed]
[26] Howel, D., Fischbacher, C.M., Bhopal, R.S., Gray, J., Metcalf, J.V. and James, O.F. (2000) An Exploratory Population-Based Case-Control Study of Primary Biliary Cirrhosis. Hepatology, 31, 1055-1060. [Google Scholar] [CrossRef] [PubMed]
[27] Shimoda, S., Nakamura, M., Ishibashi, H., Hayashida, K. and Niho, Y. (1995) HLA DRB4 0101-Restricted Immunodominant T Cell Autoepitope of Pyruvate Dehydrogenase Complex in Primary Biliary Cirrhosis: Evidence of Molecular Mimicry in Human Autoimmune Diseases. The Journal of Experimental Medicine, 181, 1835-1845. [Google Scholar] [CrossRef] [PubMed]
[28] Matsumoto, K., Ohfuji, S., Abe, M., Komori, A., Takahashi, A., Fujii, H., et al. (2021) Environmental Factors, Medical and Family History, and Comorbidities Associated with Primary Biliary Cholangitis in Japan: A Multicenter Case-Control Study. Journal of Gastroenterology, 57, 19-29. [Google Scholar] [CrossRef] [PubMed]
[29] Huang, B., Lyu, Z., Qian, Q., Chen, Y., Zhang, J., Li, B., et al. (2022) NUDT1 Promotes the Accumulation and Longevity of CD103+ TRM Cells in Primary Biliary Cholangitis. Journal of Hepatology, 77, 1311-1324. [Google Scholar] [CrossRef] [PubMed]
[30] Shimoda, S., Hisamoto, S., Harada, K., Iwasaka, S., Chong, Y., Nakamura, M., et al. (2015) Natural Killer Cells Regulate T Cell Immune Responses in Primary Biliary Cirrhosis. Hepatology, 62, 1817-1827. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., et al. (2023) A + T Rich Interaction Domain Protein 3a (Arid3a) Impairs Mertk-Mediated Efferocytosis in Cholestasis. Journal of Hepatology, 79, 1478-1490. [Google Scholar] [CrossRef] [PubMed]
[32] Li, Y., Li, Z., Chen, R., Lian, M., Wang, H., Wei, Y., et al. (2023) A Regulatory Variant at 19p13.3 Is Associated with Primary Biliary Cholangitis Risk and ARID3A Expression. Nature Communications, 14, Article No. 1732. [Google Scholar] [CrossRef] [PubMed]
[33] Hohenester, S., de Buy Wenniger, L.M., Paulusma, C.C., van Vliet, S.J., Jefferson, D.M., Oude Elferink, R.P., et al. (2012) A Biliary HCO3− Umbrella Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Human Cholangiocytes. Hepatology, 55, 173-183. [Google Scholar] [CrossRef] [PubMed]
[34] Melero, S., Spirlì, C., Zsembery, Á., Medina, J.F., Joplin, R.E., Duner, E., et al. (2002) Defective Regulation of Cholangiocyte Cl−/HCO−3 and Na+/H+ Exchanger Activities in Primary Biliary Cirrhosis. Hepatology, 35, 1513-1521. [Google Scholar] [CrossRef] [PubMed]
[35] Erice, O., Munoz-Garrido, P., Vaquero, J., Perugorria, M.J., Fernandez-Barrena, M.G., Saez, E., et al. (2018) MicroRNA-506 Promotes Primary Biliary Cholangitis-Like Features in Cholangiocytes and Immune Activation. Hepatology, 67, 1420-1440. [Google Scholar] [CrossRef] [PubMed]
[36] 尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 35-41.
[37] Hirschfield, G.M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., et al. (2017) EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Journal of Hepatology, 67, 145-172. [Google Scholar] [CrossRef] [PubMed]
[38] Lindor, K.D., Bowlus, C.L., Boyer, J., Levy, C. and Mayo, M. (2019) Primary Biliary Cholangitis: Calcium-Induced O-GlcNAc-Dependent Signaling. Hepatology, 69, 394-419. [Google Scholar] [CrossRef] [PubMed]
[39] Hen, S., Duan, W.J., You, H., Ma, X. and Jia, J.D. (2022) Recommendations of APASL Clinical Practice Guidance: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. Chinese Journal of Hepatology, 30, 196-198. [Google Scholar] [CrossRef] [PubMed]
[40] Harms, M.H., van Buuren, H.R., Corpechot, C., Thorburn, D., Janssen, H.L.A., Lindor, K.D., et al. (2019) Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 71, 357-365. [Google Scholar] [CrossRef] [PubMed]
[41] Kim, K. (2023) Diagnosis and Treatment of Primary Biliary Cholangitis. The Korean Journal of Gastroenterology, 81, 86-90. [Google Scholar] [CrossRef] [PubMed]
[42] Laschtowitz, A., de Veer, R.C., Van der Meer, A.J. and Schramm, C. (2020) Diagnosis and Treatment of Primary Biliary Cholangitis. United European Gastroenterology Journal, 8, 667-674. [Google Scholar] [CrossRef] [PubMed]
[43] Roberts, S.B., Ismail, M., Kanagalingam, G., Mason, A.L., Swain, M.G., Vincent, C., et al. (2020) Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatology Communications, 4, 1332-1345. [Google Scholar] [CrossRef] [PubMed]
[44] Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. (2016) A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine, 375, 631-643. [Google Scholar] [CrossRef] 
[45] Kowdley, K.V., Luketic, V., Chapman, R., Hirschfield, G.M., Poupon, R., Schramm, C., et al. (2018) A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. Hepatology, 67, 1890-1902. [Google Scholar] [CrossRef] [PubMed]
[46] Colapietro, F., Gershwin, M.E. and Lleo, A. (2023) PPAR Agonists for the Treatment of Primary Biliary Cholangitis: Old and New Tales. Journal of Translational Autoimmunity, 6, Article ID: 100188. [Google Scholar] [CrossRef] [PubMed]
[47] Corpechot, C., Poupon, R. and Chazouillères, O. (2019) New Treatments/Targets for Primary Biliary Cholangitis. JHEP Reports, 1, 203-213. [Google Scholar] [CrossRef] [PubMed]
[48] Nakai, S., Masaki, T., Kurokohchi, K., Deguchi, A. and Nishioka, M. (2000) Combination Therapy of Bezafibrate and Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Preliminary Study. The American Journal of Gastroenterology, 95, 326-327. [Google Scholar] [CrossRef] [PubMed]
[49] Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., et al. (2018) A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 378, 2171-2181. [Google Scholar] [CrossRef] [PubMed]
[50] Tanaka, A., Hirohara, J., Nakano, T., Matsumoto, K., Chazouillères, O., Takikawa, H., et al. (2021) Association of Bezafibrate with Transplant-Free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 75, 565-571. [Google Scholar] [CrossRef] [PubMed]
[51] Grigorian, A.Y., Mardini, H.E., Corpechot, C., Poupon, R. and Levy, C. (2015) Fenofibrate Is Effective Adjunctive Therapy in the Treatment of Primary Biliary Cirrhosis: A Meta-Analysis. Clinics and Research in Hepatology and Gastroenterology, 39, 296-306. [Google Scholar] [CrossRef] [PubMed]
[52] Guo, C., Zhang, Y., He, L., Wang, F., Chen, K., Li, J., et al. (2015) Combination Therapy of Fenofibrate and Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to UDCA Monotherapy: A Meta-Analysis. Drug Design, Development and Therapy, 9, 2757-2766. [Google Scholar] [CrossRef] [PubMed]
[53] Kowdley, K.V., Bowlus, C.L., Levy, C., Akarca, U.S., Alvares-da-Silva, M.R., Andreone, P., et al. (2024) Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal of Medicine, 390, 795-805. [Google Scholar] [CrossRef] [PubMed]
[54] Hirschfield, G.M., Bowlus, C.L., Mayo, M.J., Kremer, A.E., Vierling, J.M., Kowdley, K.V., et al. (2024) A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. New England Journal of Medicine, 390, 783-794. [Google Scholar] [CrossRef] [PubMed]
[55] Hirschfield, G.M., Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., et al. (2021) A Placebo-Controlled Randomised Trial of Budesonide for PBC Following an Insufficient Response to UDCA. Journal of Hepatology, 74, 321-329. [Google Scholar] [CrossRef] [PubMed]
[56] Guo, C., Zhang, H., Yang, J., Zhu, R., Zheng, Y., Dai, W., et al. (2015) Combination Therapy of Ursodeoxycholic Acid and Budesonide for PBC-AIH Overlap Syndrome: A Meta-Analysis. Drug Design, Development and Therapy, 9, 567-574. [Google Scholar] [CrossRef] [PubMed]
[57] Al‐Harthy, N., Kumagi, T., Coltescu, C. and Hirschfield, G.M. (2010) The Specificity of Fatigue in Primary Biliary Cirrhosis: Evaluation of a Large Clinic Practice. Hepatology, 52, 562-570. [Google Scholar] [CrossRef] [PubMed]
[58] Tsuda, M., Moritoki, Y., Lian, Z., Zhang, W., Yoshida, K., Wakabayashi, K., et al. (2012) Biochemical and Immunologic Effects of Rituximab in Patients with Primary Biliary Cirrhosis and an Incomplete Response to Ursodeoxycholic Acid. Hepatology, 55, 512-521. [Google Scholar] [CrossRef] [PubMed]
[59] Myers, R.P., Swain, M.G., Lee, S.S., Shaheen, A.A.M. and Burak, K.W. (2013) B-Cell Depletion with Rituximab in Patients with Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid. American Journal of Gastroenterology, 108, 933-941. [Google Scholar] [CrossRef] [PubMed]
[60] Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A., Newton, J.L., et al. (2018) Rituximab for the Treatment of Fatigue in Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis): A Randomised Controlled Trial. Efficacy and Mechanism Evaluation, 5, 1-78. [Google Scholar] [CrossRef] 
[61] Yang, C., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N.P., et al. (2014) IL-12/Th1 and IL-23/Th17 Biliary Microenvironment in Primary Biliary Cirrhosis: Implications for Therapy. Hepatology, 59, 1944-1953. [Google Scholar] [CrossRef] [PubMed]
[62] Hirschfield, G.M., Gershwin, M.E., Strauss, R., Mayo, M.J., Levy, C., Zou, B., et al. (2016) Ustekinumab for Patients with Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof‐of‐Concept Study. Hepatology, 64, 189-199. [Google Scholar] [CrossRef] [PubMed]

为你推荐